CN101883785B - 新的非选择性生长抑素类似物 - Google Patents

新的非选择性生长抑素类似物 Download PDF

Info

Publication number
CN101883785B
CN101883785B CN200880118937.1A CN200880118937A CN101883785B CN 101883785 B CN101883785 B CN 101883785B CN 200880118937 A CN200880118937 A CN 200880118937A CN 101883785 B CN101883785 B CN 101883785B
Authority
CN
China
Prior art keywords
phe
lys
tyr
pro
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880118937.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN101883785A (zh
Inventor
A·维塔利
M·皮诺里
P·马斯卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20072266 external-priority patent/ITMI20072266A1/it
Priority claimed from EP07425778A external-priority patent/EP2067786A1/en
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CN101883785A publication Critical patent/CN101883785A/zh
Application granted granted Critical
Publication of CN101883785B publication Critical patent/CN101883785B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN200880118937.1A 2007-12-03 2008-11-24 新的非选择性生长抑素类似物 Active CN101883785B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI20072266 ITMI20072266A1 (it) 2007-12-03 2007-12-03 Nuovi analoghi non selettivi di somatostatina
ITMI2007A002266 2007-12-03
EP07425778A EP2067786A1 (en) 2007-12-07 2007-12-07 Novel non selective analogs of somatostatin
EP07425778.3 2007-12-07
PCT/EP2008/066081 WO2009071460A2 (en) 2007-12-03 2008-11-24 New non-selective somatostatin analogues

Publications (2)

Publication Number Publication Date
CN101883785A CN101883785A (zh) 2010-11-10
CN101883785B true CN101883785B (zh) 2014-01-15

Family

ID=40667736

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880118937.1A Active CN101883785B (zh) 2007-12-03 2008-11-24 新的非选择性生长抑素类似物

Country Status (15)

Country Link
US (1) US8937152B2 (enExample)
EP (1) EP2225271B1 (enExample)
JP (1) JP5331817B2 (enExample)
KR (1) KR101500528B1 (enExample)
CN (1) CN101883785B (enExample)
BR (1) BRPI0818978B8 (enExample)
CA (1) CA2702940C (enExample)
CY (1) CY1114490T1 (enExample)
DK (1) DK2225271T3 (enExample)
ES (1) ES2431573T3 (enExample)
HR (1) HRP20130948T1 (enExample)
PL (1) PL2225271T3 (enExample)
PT (1) PT2225271E (enExample)
SI (1) SI2225271T1 (enExample)
WO (1) WO2009071460A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2013032012A1 (ja) * 2011-09-04 2013-03-07 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
DK3007704T3 (da) * 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Kombinationsterapi til akromegali
CN103467575B (zh) * 2013-08-22 2016-03-02 深圳翰宇药业股份有限公司 一种帕西瑞肽的制备方法
CN103641894B (zh) * 2013-12-06 2015-10-28 深圳翰宇药业股份有限公司 一种治疗库欣病的多肽药物的制备方法
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
CN104447962B (zh) * 2014-12-29 2018-07-17 成都圣诺生物科技股份有限公司 一种合成帕瑞肽的方法
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2020064693A1 (en) * 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
GB201816637D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists
US20240165282A1 (en) * 2021-03-04 2024-05-23 Starget Pharma Ltd. Conformational constrained somatostatin receptor 3 peptide ligands and their conjugates and uses thereof
IT202100032615A1 (it) 2021-12-24 2023-06-24 Italfarmaco Spa Uso di un agonista della somatostatina nel trattamento di tumori che esprimono SSTR3
CN119708199A (zh) * 2023-09-27 2025-03-28 钱杭江医药科技(嘉兴)有限公司 生长抑素肽类类似物、螯合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001579A2 (en) * 1995-06-29 1997-01-16 Novartis Ag Somatostatin peptides
CN1832962A (zh) * 2003-08-08 2006-09-13 诺瓦提斯公司 促生长素抑制素肽的制备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6365380B2 (en) 2000-02-23 2002-04-02 Pcbu Services, Inc. Method for stereoselectively inverting a chiral center of a chemical compound using an enzyme and a metal catalyst
AU2003212430B2 (en) * 2002-03-12 2006-05-25 Noxell Corporation Cosmetic composition comprising double coated pigment
GB0206415D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Deracemisation of amines
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
AU2004294269A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Biomarkers for the efficacy of somatostatin analogue treatment
ITFI20040057A1 (it) * 2004-03-10 2004-06-10 Mauro Giuntini Analoghi della somatostatina
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US7824663B2 (en) * 2005-03-10 2010-11-02 Kokyu Alcohol Kogyo Co., Ltd. Lip gloss composition
SI1787658T1 (sl) * 2005-11-10 2012-07-31 Chemi Spa Formulacije z trajnim sproščanjem somatostatin analognih inhibitorjev rastnega hormona
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001579A2 (en) * 1995-06-29 1997-01-16 Novartis Ag Somatostatin peptides
CN1832962A (zh) * 2003-08-08 2006-09-13 诺瓦提斯公司 促生长素抑制素肽的制备

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chruscinska E et al.Unusual gain in the coordinationa ability of vasopressin-like peptides towards cu<2+> ions by insertion of the highly hydrophobic side chain.《New Journal of Chemistry》.2003,第27卷(第2期),251-256. *
KOSTENICH ET AL.Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin.《Lung Cancer》.2005,第50卷(第3期),319-328. *

Also Published As

Publication number Publication date
PL2225271T3 (pl) 2013-12-31
CA2702940A1 (en) 2009-06-11
US20100323964A1 (en) 2010-12-23
CA2702940C (en) 2016-09-13
BRPI0818978A2 (pt) 2016-05-03
BRPI0818978B1 (pt) 2019-09-10
CN101883785A (zh) 2010-11-10
WO2009071460A2 (en) 2009-06-11
ES2431573T3 (es) 2013-11-27
KR101500528B1 (ko) 2015-03-09
EP2225271B1 (en) 2013-07-31
DK2225271T3 (da) 2013-10-07
WO2009071460A3 (en) 2009-12-17
CY1114490T1 (el) 2016-10-05
EP2225271A2 (en) 2010-09-08
KR20100103464A (ko) 2010-09-27
SI2225271T1 (sl) 2013-10-30
JP2011505345A (ja) 2011-02-24
PT2225271E (pt) 2013-09-27
HRP20130948T1 (hr) 2013-11-08
US8937152B2 (en) 2015-01-20
BRPI0818978B8 (pt) 2021-05-25
JP5331817B2 (ja) 2013-10-30

Similar Documents

Publication Publication Date Title
JP5331817B2 (ja) 新規な非選択的ソマトスタチン類似体
CA2222524C (en) Somatostatin peptides
CA2666642C (en) Receptor(sstr2)-selective somatostatin antagonists
US20070154392A1 (en) Treatment process using somatostatin analogues
JP2002518339A (ja) コンフォメーション的に拘束された主鎖環化ソマトスタチン類似体
JP2014129382A (ja) ソマトスタチン受容体２アンタゴニスト
RU2329273C2 (ru) Химерные аналоги лигандов соматостатиновых и допаминовых рецепторов, фармацевтические композиции на их основе и способы воздействия на рецепторы соматостатина и/или допамина
US20130035286A1 (en) Pharmaceutical Composition Comprising Cyclic Somatostatin Analogues
WO2010065572A1 (en) Sstr1-selective analogs
SK2094A3 (en) Somatostatine polypeptides, method of their preparing and using
EP1189941B1 (en) Neuromedin b and somatostatin receptor agonists
US20080132453A1 (en) Neuromedin B and somatostatin receptor agonists
EP2067786A1 (en) Novel non selective analogs of somatostatin
CN1812997B (zh) 包含促生长素抑制素类似物的胃肠外药物组合物
ITMI20072266A1 (it) Nuovi analoghi non selettivi di somatostatina
EP4656654A1 (en) Somatostatin peptide analogue, chelate and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant